Skip to main content

Geriatric Urogynecology & Reconstructive Urology

Geriatric urogynecology and reconstructive urology addresses the unique challenges of managing pelvic floor disorders (PFDs) — pelvic organ prolapse (POP), urinary incontinence (UI), fecal incontinence (FI), and genitourinary syndrome of menopause (GSM) — in older women, a population expected to grow by 46% by 2050.[1] The central principle is that chronological age alone should not determine treatment eligibility; rather, individualized decisions should be guided by frailty status, comorbidity burden, functional capacity, patient goals, and life expectancy.[2][3]

Epidemiology and Impact​

UI prevalence reaches approximately 75% in women aged ≥75 years, yet at least half do not report it to their physicians.[4] POP prevalence similarly increases with age, and roughly 13% of women undergo prolapse surgery in their lifetime.[5] These conditions are major drivers of nursing-home admission (6% of admissions for elderly women) and carry enormous economic burden ($19.5 billion annually in the U.S.).[4] Mixed incontinence becomes increasingly common with age, and the distinction between stress and urgency UI is often less clear in older women.[4][6]

Preoperative Geriatric Assessment and Frailty​

Frailty screening is essential before any elective pelvic-floor surgery in women ≥65 years. Frailty — a multidimensional syndrome of decreased physiologic reserve — is present in 30–50% of older patients presenting for major surgery and independently predicts postoperative morbidity, mortality, loss of independence, and prolonged hospitalization.[7][8]

For the urogynecologic setting:[3][9][7]

  • Timed Up and Go (TUG) — ≥15 seconds indicates compromised mobility.
  • Clinical Frailty Scale (CFS-9) — rapid, picture-based; AUC 0.86–0.91 vs. Fried Frailty Index in pelvic-floor patients.[9]
  • Mini-Cog — screens for cognitive impairment (critical for medication management and self-catheterization capacity).
  • Robinson Frailty Index — used in the ASPIRe trial; scores ≥2 indicate prefrail / frail status.[10]
  • Life-Space Assessment — evaluates mobility and community engagement.

At minimum, the TUG, Life-Space Assessment, and Mini-Cog should be performed preoperatively in patients ≥65 years planning pelvic-floor surgery.[3]

ASPIRe frailty substudy​

ASPIRe (2026, n = 146 women ≥65 years undergoing prolapse surgery) found that prefrail / frail participants had no increase in immediate postoperative complications compared with nonfrail patients, but had a 2.1-fold higher hazard of treatment failure (aHR 2.1, 95% CI 1.2–3.6). Those living alone were more likely to require enhanced social support in the first 6 weeks (19% vs. 6%, P = 0.04).[10]

Comprehensive geriatric assessment should also address polypharmacy (particularly anticholinergic burden — see below), nutritional status, depression screening (PHQ-2), goals of care, and advance-care planning.[11][7]

Prehabilitation and ERAS​

Multimodal prehabilitation — combining exercise training, nutritional optimization, and anxiety reduction — is strongly recommended for frail older adults before major surgery (ASCRS Grade 1B).[12] A systematic review of 26 studies demonstrated that prehabilitation reduced overall complications (OR 0.61), pulmonary complications (OR 0.41), and cardiac complications (OR 0.46) after major abdominal surgery.[12]

ERAS protocols specifically adapted for transvaginal pelvic-floor reconstruction in older women have been evaluated in a 2025 RCT (n = 100), demonstrating significantly shorter postoperative length of stay (65 vs. 74 hours, P < 0.01) along with reductions in postoperative pain scores and PONV.[13][14]

Nonsurgical Management of UI in Older Women​

Behavioral and conservative therapies remain first-line for all types of UI in older women:[15][4]

  • Pelvic floor physical therapy / PFMT — effective for stress, urgency, and mixed UI; ~50% satisfaction at 1 year for stress-predominant UI.[15]
  • Bladder training — timed voiding, urge-suppression techniques.
  • Fluid management — limiting intake to ≤2 L/day, reducing caffeine, decreasing evening fluids for nocturia.[15]
  • Weight loss — for obese women, combined with exercise.

A 2025 systematic review of conservative interventions in frail older adults (12 RCTs, n = 1,580) found a beneficial but not statistically significant reduction in objective UI measures (g = −0.39, P = 0.09), with very low certainty of evidence. Importantly, no adverse events were reported, supporting the safety of these interventions even in frail populations.[16]

Pessaries are particularly valuable in the geriatric population — even very frail women can be managed with pessaries changed every 4–6 weeks in clinic. Caregivers of patients with dementia should be aware of the need for regular pessary changes to avoid complications.[17][18]

Pharmacotherapy: The Anticholinergic Burden Problem​

This is one of the most critical geriatric-specific considerations in urogynecology. Chronic anticholinergic use for OAB is associated with a dose-dependent increased risk of dementia:[19][20][21]

  • A large French nested case-control study (n = 28,860) found an adjusted OR of 1.48 (95% CI 1.22–1.80) for dementia with >365 defined daily doses of OAB anticholinergics. Oxybutynin and solifenacin carried the highest risk, while trospium (which does not cross the blood-brain barrier) showed no increased risk.[19]
  • A 2025 meta-analysis (n = 3.66 million) confirmed a 20% increased dementia risk with anticholinergics vs. no therapy (RR 1.2) and a 28% increased risk vs. mirabegron (RR 1.28).[21]
  • A 2026 systematic review found pooled HR of 1.24 (95% CI 1.19–1.30) for cognitive decline / dementia, plus increased cardiovascular risk (OR 1.13) and mortality (OR 1.26) with bladder antimuscarinics in older women.[22]

Society recommendations​

  • The SUFU White Paper states that chronic use (>3 months) of OAB anticholinergics is "likely associated with an increased risk of new-onset dementia" and recommends earlier progression to advanced therapies (botulinum toxin, neuromodulation).[20]
  • The AGS Beers Criteria lists anticholinergic OAB medications as potentially inappropriate for elderly individuals.[23]
  • The AUGS explicitly recommends avoiding anticholinergics in patients >70 years.[23]

Preferred pharmacologic alternatives​

β3-adrenergic agonists (mirabegron, vibegron) have equivalent efficacy to anticholinergics for OAB symptoms but do not contribute to anticholinergic burden.[24][25][26] In a network meta-analysis of older adults (≥65 years), mirabegron had:[24]

  • Similar efficacy across all endpoints (micturition frequency, incontinence episodes, urgency).
  • Dry-mouth incidence similar to placebo (vs. 3.8–7.9× higher with antimuscarinics).
  • No increased odds of adverse-event-related discontinuation (OR 0.99 vs. placebo).

Mild blood-pressure elevation (3–10 mmHg systolic) is the primary concern with β3 agonists; blood pressure should be monitored.[27]

Third-Line Therapies in Older Women​

When conservative and pharmacologic measures fail:

  • OnabotulinumtoxinA (Botox) — FDA-approved for OAB refractory to anticholinergics / β3 agonists; effective in older women but carries risk of urinary retention requiring self-catheterization (which may be impractical with limited dexterity or cognitive impairment).[28][18]
  • Percutaneous tibial nerve stimulation (PTNS) — office-based, minimally invasive; 30-minute weekly sessions for 12 weeks then maintenance. Effective for urgency UI with very few side effects, making it well suited for elderly patients who cannot tolerate medications or are poor surgical candidates. A network meta-analysis found PTNS was the most effective non-implantable electrical-stimulation modality for symptom-severity reduction.[29][30]
  • Sacral neuromodulation (SNM) — more invasive (implanted device); success rates of 29–76% for ≥50% improvement in leakage. Importantly, poor response to PTNS does not predict failure of SNM — a negative PTNS trial should not preclude an SNM trial. SNM is also FDA-approved for fecal incontinence.[31][32]

Surgical Management of POP in Geriatric Patients​

Patient selection​

FactorConsideration
Frailty statusPrefrail / frail patients have 2.1× higher treatment failure; plan for enhanced social support postoperatively
Cardiovascular diseaseIndependent risk factor for perioperative complications (blood transfusion, pulmonary edema, CHF); CAD and PVD are strongest predictors
Cognitive statusAffects ability to manage pessaries, perform CIC, adhere to postoperative restrictions; screen with Mini-Cog
Sexual activity goalsDetermines whether obliterative vs. reconstructive approach is appropriate
ASA classHigher ASA associated with colpocleisis selection; however, ASA / CCI alone do not reliably predict complications
Life expectancyInfluences whether durable repair (sacrocolpopexy) vs. simpler procedure is warranted

Surgical approaches by geriatric context​

Colpocleisis (obliterative surgery) is a highly effective option for elderly women who do not desire vaginal preservation. ACOG recommends it as a first-line surgical treatment for women with significant comorbidities.[17] Key outcomes:[33][35]

  • In women ≥75 years, colpocleisis patients are older with more comorbidities than those undergoing reconstructive repair, yet have equivalent complication rates and shorter LOS (1.2 vs. 1.7 days, P = 0.03).[33]
  • A 2026 single-center series (n = 58, mean age 75.6 years) reported 94.8% anatomic success, 77.5% subjective success, and only a 6.8% regret rate at mean 2.9-year follow-up. No patients regretted loss of sexual function. Significant improvements were seen in all pelvic-symptom domains (PFDI-20 decreased from 78.1 to 16.6, P < 0.001).[35]

Vaginal native-tissue repair remains the most common reconstructive approach in women ≥75 years (43.7% of prolapse repairs in this age group), followed by colpocleisis (42.3%) and sacrocolpopexy (14%).[33]

Sacrocolpopexy offers the most durable anatomic outcomes, but involves longer operative time and greater physiologic stress. In ASPIRe, frail patients undergoing any approach (including sacrocolpopexy) had few immediate complications, but higher long-term treatment failure.[10]

Complications in the elderly​

A retrospective study of 267 women ≥75 years found a 25.8% perioperative complication rate, with the most common being blood transfusion / significant blood loss, pulmonary edema, and postoperative CHF. Independent risk factors were operative time, coronary artery disease, and peripheral vascular disease — not age or comorbidity indices alone.[34] A large single-center study of women ≥80 years (n = 720) found that intraoperative complications occurred in only 1.5% and postoperative complications were mainly minor (Clavien-Dindo I–II), with no procedure-related deaths.[2]

Septuagenarians and older patients have an approximately 3-fold higher risk of mild early postoperative complications (OR 2.86, 95% CI 1.76–4.66) but no increase in major complications compared with younger patients.[36]

Genitourinary Syndrome of Menopause (GSM)​

GSM is a chronic, progressive condition affecting 45–77% of postmenopausal women, with symptoms worsening with age and time since menopause.[37] See GSM for the full framework. Geriatric-specific points:

  • Vaginal estrogen reduces recurrent UTIs — a major source of morbidity, hospitalization, and antibiotic use in elderly women.[39][40]
  • Vaginal estrogen diminishes urinary urgency (unlike oral systemic estrogen, which increased incontinence in the WHI trial).[39]
  • All vaginal estrogen preparations (creams, tablets, rings) are equally effective; 60–80% subjective symptom improvement.[37][38]
  • Despite the absence of evidence that vaginal estrogen increases breast cancer, endometrial cancer, cardiovascular, or thromboembolic risk, it carries the same boxed warning as systemic HT — a significant barrier to prescribing.[37][39]
  • Progestogen is not needed for endometrial protection with low-dose vaginal estrogen based on 1-year safety data; postmenopausal bleeding nonetheless requires evaluation.[39]
  • Vaginal estrogen is dramatically underutilized — only 2.2–4.2% of eligible postmenopausal women receive it.[37]

Non-estrogen alternatives include vaginal DHEA (prasterone), oral ospemifene, and vaginal moisturizers / lubricants.[41][42]

Fecal Incontinence in Older Women​

FI prevalence increases markedly with age and is a leading cause of nursing-home placement. Management principles in the elderly:[32]

  • Conservative first — dietary fiber, stool-bulking agents, loperamide, biofeedback.
  • Sacral neuromodulation — first-line surgical treatment regardless of sphincter integrity; success rates ~63% at 6–12 months, declining to ~54% long-term.[32]
  • Sphincteroplasty — considered when EAUS demonstrates a discrete sphincter defect, though outcomes deteriorate over time.
  • PTNS — insufficient evidence for routine use in FI; an RCT showed no significant difference vs. sham (38% vs. 31% response).[32]

For diagnostic workup, see Anorectal Function & Defecography.

Summary of Geriatric-Specific Principles​

DomainKey Geriatric Principle
AssessmentScreen for frailty (TUG, CFS, Mini-Cog) rather than relying on chronological age; comprehensive geriatric assessment before elective surgery
MedicationsAvoid chronic anticholinergics (dementia risk); prefer β3 agonists (mirabegron / vibegron); review total anticholinergic burden
Conservative RxPessaries are safe even in very frail / demented patients with caregiver support; PFMT and behavioral therapy remain first-line
Vaginal estrogenUnderutilized; reduces UTIs, urgency, and vaginal symptoms; safe in low doses without progestogen
Surgical selectionColpocleisis is first-line for comorbid patients not desiring vaginal preservation; equivalent complications with shorter LOS
Perioperative careERAS protocols reduce LOS, pain, and PONV; prehabilitation improves functional capacity and reduces complications
Postoperative planningFrail patients need enhanced social support for 6 weeks; higher long-term treatment failure with frailty
Third-line therapiesPTNS is well suited for elderly (office-based, minimal side effects); Botox effective but self-catheterization may be impractical
Goals of careShared decision-making incorporating life expectancy, functional goals, sexual-activity preferences, and caregiver capacity

Cross-references​

References​

1. Rashid TF, Alkassis M, Griebling TL, et al. "Management Approaches for Advanced Pelvic Organ Prolapse in the Geriatric Population." Clin Geriatr Med. 2025;41(2):275-288. doi:10.1016/j.cger.2025.01.008

2. Kołodyńska A, Kamińska A, Strużyk A, et al. "Geripausal Women — a New Challenge for Urogynecology in Upcoming Years." J Clin Med. 2026;15(2):530. doi:10.3390/jcm15020530

3. Shaw JS, Erekson E, Richter HE. "The Impact of Frailty in Older Women Undergoing Pelvic Floor Reconstructive Surgery." Menopause. 2020;28(3):332-336. doi:10.1097/GME.0000000000001681

4. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline From the American College of Physicians." Ann Intern Med. 2014;161(6):429-440. doi:10.7326/M13-2410

5. Raju R, Linder BJ. "Evaluation and Management of Pelvic Organ Prolapse." Mayo Clin Proc. 2021;96(12):3122-3129. doi:10.1016/j.mayocp.2021.09.005

6. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. "Urinary Incontinence in Women: A Review." JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137

7. Kim DH, Rockwood K. "Frailty in Older Adults." N Engl J Med. 2024;391(6):538-548. doi:10.1056/NEJMra2301292

8. McIsaac DI, MacDonald DB, Aucoin SD. "Frailty for Perioperative Clinicians: A Narrative Review." Anesth Analg. 2020;130(6):1450-1460. doi:10.1213/ANE.0000000000004602

9. Amin KA, Lee W, Moskowitz D, et al. "A Rapid Method to Preoperatively Assess Frailty for Older Patients With Pelvic Floor Conditions." J Urol. 2020;203(6):1172-1177. doi:10.1097/JU.0000000000000739

10. Erekson E, Menefee SA, Whitworth R, et al. "Outcomes by Frailty and Mobility in Older Patients Undergoing Major Urogynecologic Surgery: A Planned Supplementary Study of the ASPIRe Trial." Am J Obstet Gynecol. 2026;234(3):689-729. doi:10.1016/j.ajog.2025.11.002

11. Zietlow KE, Wong S, Heflin MT, et al. "Geriatric Preoperative Optimization: A Review." Am J Med. 2022;135(1):39-48. doi:10.1016/j.amjmed.2021.07.028

12. Saur NM, Davis BR, Montroni I, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Perioperative Evaluation and Management of Frailty Among Older Adults Undergoing Colorectal Surgery." Dis Colon Rectum. 2022;65(4):473-488. doi:10.1097/DCR.0000000000002410

13. Huang X, Deng S, Lei X, et al. "Effect of Enhanced Recovery After Surgery on Older Patients Undergoing Transvaginal Pelvic Floor Reconstruction Surgery: A Randomised Controlled Trial." BMC Med. 2025;23(1):43. doi:10.1186/s12916-025-03880-y

14. Xiao Y, Hong S, Wan Y, et al. "Exploration of Enhanced Recovery After Surgery in Female Pelvic Floor Reconstruction: A Retrospective Study." Front Med. 2025;12:1659074. doi:10.3389/fmed.2025.1659074

15. ACOG Practice Bulletin No. 155. "Urinary Incontinence in Women." Obstet Gynecol. 2015;126(5):e66-e81. doi:10.1097/AOG.0000000000001148

16. O'Callaghan M, Robinson K, Whiston A, Senter M, Clifford AM. "The Effect of Conservative Non-Pharmacological Interventions on the Management of Urinary Incontinence in Older Adults Living With Frailty: Systematic Review and Meta-Analysis." PLoS One. 2025;20(5):e0322742. doi:10.1371/journal.pone.0322742

17. ACOG Practice Bulletin No. 214. "Pelvic Organ Prolapse." Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

18. Goode PS, Burgio KL, Richter HE, Markland AD. "Incontinence in Older Women." JAMA. 2010;303(21):2172-2181. doi:10.1001/jama.2010.749

19. Malcher MF, Droupy S, Berr C, et al. "Dementia Associated With Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database." J Urol. 2022;208(4):863-871. doi:10.1097/JU.0000000000002804

20. Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. "SUFU White Paper on Overactive Bladder Anticholinergic Medications and Dementia Risk." Neurourol Urodyn. 2022;41(8):1928-1933. doi:10.1002/nau.25037

21. Kotochinsky M, Mora L, Carrazzoni Godoi D, et al. "Risk of Dementia in Patients Treated With Anticholinergics for Overactive Bladder Syndrome: A Systematic Review and Meta-Analysis." Neurol Sci. 2025. doi:10.1007/s10072-025-08546-4

22. Maguire T, Marr C, Barry H, Abdel-Fattah M, McGuinness B. "Antimuscarinic Medication Used for the Treatment of Overactive Bladder in Women and the Risk of Cognitive Decline, Cardiovascular Disease and Mortality: A Systematic Review." Age Ageing. 2026;55(2):afag027. doi:10.1093/ageing/afag027

23. Luchristt D, Bretschneider CE, Kenton K, Simon M, Brown O. "Inequities in Filled Overactive Bladder Medication Prescriptions in the US." JAMA Netw Open. 2023;6(5):e2315074. doi:10.1001/jamanetworkopen.2023.15074

24. Lozano-Ortega G, Walker DR, Johnston K, et al. "Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-Analysis." Drugs Aging. 2020;37(11):801-816. doi:10.1007/s40266-020-00792-9

25. Kelleher C, Hakimi Z, Zur R, et al. "Efficacy and Tolerability of Mirabegron Compared With Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-Analysis." Eur Urol. 2018;74(3):324-333. doi:10.1016/j.eururo.2018.03.020

26. Wagg A, Nitti VW, Kelleher C, et al. "Oral Pharmacotherapy for Overactive Bladder in Older Patients: Mirabegron as a Potential Alternative to Antimuscarinics." Curr Med Res Opin. 2016;32(4):621-638. doi:10.1185/03007995.2016.1149806

27. Wei JT, Dauw CA, Brodsky CN. "Lower Urinary Tract Symptoms in Men." JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045

28. U.S. Food and Drug Administration. "FDA Orange Book — Botulinum Toxin Type A."

29. Tutolo M, Ammirati E, Heesakkers J, et al. "Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-Neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature." Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002

30. Yu TY, Yu CY, Escorpizo R, et al. "Comparison of Nonimplantable Electrical Stimulation in Women With Urinary Incontinence: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials." Sci Rep. 2024;14(1):26957. doi:10.1038/s41598-024-78358-7

31. Kapriniotis K, Jenks J, Toia B, et al. "Does Response to Percutaneous Tibial Nerve Stimulation Predict Similar Outcome to Sacral Nerve Stimulation?" Neurourol Urodyn. 2022;41(5):1172-1176. doi:10.1002/nau.24944

32. ACOG Practice Bulletin No. 210. "Fecal Incontinence." Obstet Gynecol. 2019;133(4):e260-e273. doi:10.1097/AOG.0000000000003187

33. Drain A, Escobar C, Pape D. "Prolapse Repair in the Elderly Patient: Contemporary Trends and 30-Day Perioperative Complications." Int Urogynecol J. 2020;31(10):2095-2100. doi:10.1007/s00192-020-04365-7

34. Stepp KJ, Barber MD, Yoo EH, et al. "Incidence of Perioperative Complications of Urogynecologic Surgery in Elderly Women." Am J Obstet Gynecol. 2005;192(5):1630-1636. doi:10.1016/j.ajog.2004.11.026

35. Yildiz Ç, Özdemir AZ, Barutçu B, et al. "Colpocleisis as an Obliterative Surgery for Pelvic Organ Prolapse: A Single-Center Experience." Medicine (Baltimore). 2026;105(4):e46411. doi:10.1097/MD.0000000000046411

36. Joukhadar R, Wöckel A, Herr D, et al. "Challenges of Longevity: Safety of Vaginal and Laparoscopic Urogynecological Procedures in Septuagenarians and Older Patients." Biomed Res Int. 2016;2016:5184595. doi:10.1155/2016/5184595

37. Gallo K, Zhang CA, Burton C, Kamdar N, Enemchukwu EA. "Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause." JAMA Netw Open. 2025;8(12):e2549822. doi:10.1001/jamanetworkopen.2025.49822

38. Lethaby A, Ayeleke RO, Roberts H. "Local Oestrogen for Vaginal Atrophy in Postmenopausal Women." Cochrane Database Syst Rev. 2016;(8):CD001500. doi:10.1002/14651858.CD001500.pub3

39. Pinkerton JV. "Hormone Therapy for Postmenopausal Women." N Engl J Med. 2020;382(5):446-455. doi:10.1056/NEJMcp1714787

40. Hickey M, LaCroix AZ, Doust J, et al. "An Empowerment Model for Managing Menopause." Lancet. 2024;403(10430):947-957. doi:10.1016/S0140-6736(23)02799-X

41. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400-1414. doi:10.7326/ANNALS-24-00610

42. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28-39.